Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

235.74
-26.4200-10.08%
Post-market: 233.72-2.0200-0.86%19:19 EDT
Volume:1.88M
Turnover:458.00M
Market Cap:30.52B
PE:-108.19
High:259.16
Open:257.14
Low:235.57
Close:262.16
Loading ...

Company Profile

Company Name:
Alnylam Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
2230
Office Location:
675 West Kendall Street,Henri A. Termeer Square,Cambridge,Massachusetts,United States
Zip Code:
02142
Fax:
617 551 8101
Introduction:
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
John M. Maraganore
Chief Executive Officer and Director
Michael W. Bonney
Chair of the Board
Amy W. Schulman
Director
David E.I. Pyott
Director
Dennis A. Ausiello
Director
John K. Clarke
Director
Kevin P. Starr
Director
Marsha H. Fanucci
Director
Paul R. Schimmel
Director
Phillip A. Sharp
Director
Steven M. Paul
Director

Shareholders

Name
Position
John M. Maraganore
Chief Executive Officer and Director
Yvonne Greenstreet
Executive Vice President and Chief Operating Officer
Laurie B. Keating
Senior Vice President, General Counsel and Secretary
Akshay K. Vaishnaw
Executive Vice President, Research and Development
Barry E. Greene
President
Michael P. Mason
Vice President of Finance and Treasurer